.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The GBM AGILE trial recently released critical survival results for Regorafenib for Glioblastoma. Initially, earlier phase studies suggested potential benefits for this multikinase inhibitor in treating brain tumors. However, this large-scale registration trial failed to confirm survival advantages in newly diagnosed or recurrent settings. Consequently, these findings significantly impact how clinicians approach therapy for aggressive gliomas.
Specifically, the trial enrolled patients with newly diagnosed unmethylated (NDU) and recurrent disease (RD). Participants received regorafenib or standard-of-care controls like temozolomide or lomustine. Furthermore, the statistical analysis utilized a Bayesian adaptive design to monitor efficacy closely. Unfortunately, the results showed median overall survival (OS) did not improve with regorafenib. For example, OS was 12.0 months in NDU patients compared to 13.7 months in the control group. Similarly, RD patients saw 8.0 months with regorafenib versus 9.2 months with lomustine.
Moreover, researchers noted increased toxicity levels in the regorafenib arm relative to the control arms. Because of these results, the drug did not meet the predefined criteria for superiority. Therefore, oncology guidelines have started removing regorafenib as a recommended option for recurrent glioblastoma. In summary, while the platform effectively tested the drug, regorafenib provides no survival benefit for these patients.
The trial found that regorafenib did not improve overall survival in patients with either newly diagnosed unmethylated or recurrent glioblastoma when compared to standard treatments.
Notably, the regorafenib arm was associated with increased toxicity compared to the control treatments, which included temozolomide and lomustine.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Wen PY et al. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. J Clin Oncol. 2026 Apr 14. doi: 10.1200/JCO-25-01137. PMID: 41980234.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The GBM AGILE trial found that regorafenib did not improve overall survival in newly diagnosed or recurrent glioblastoma, leading to its removal from guidel...
4 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
A prospective cohort study demonstrates that poor adolescent sleep quality, especially long sleep latency and reduced efficiency, increases dysmenorrhea severity in young adulthood. Addressing adolescent rest patterns offers a critical preventive avenue for clinicians.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
